An observational study in Primary Aldosteronism and High Blood Pressure, sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Queen Mary University of London · Observational
The goal of this observational study is to see if there is a cyclical or exaggerated diurnal variation in aldosterone production in people with Primary Aldosteronism.
The main questions it aims to answer are:
Participants will have a 24 hour urine measurement. They will also have multiple blood tests throughout the day to study the variability in aldosterone secretion.
People with hypertension.
Exclusion Criteria:
Sensitivity and specificity of 24 hour urine tetrahydroaldosterone excretion.
Can measurement of 24 hour urine tetrahydroaldosterone excretion detect more people with PA than current conventional screening tests?
Time frame: 12 months
Differences in timed day and night urine THA measurements.
We will be measuring the 24 hour urine THA samples in two separate (approximately 12 hours each) collections, one in the day and one at night. We can then study if there are any differences between day time and night time secretion which may help us understand the diurnal variation in aldosterone secretion.
Time frame: 12 months
Variation in aldosterone secretion from day series in those with positive 24h urine THA and those with negative 24h urine THA.
This will allow us to study further if the reason why their screening blood test did not meet the threshold for diagnosis.
Time frame: 12 months
Complete or partial clinical cure rate of this cohort of patients that qualify for adrenalectomy
Complete clinical cure is daytime home or ambulatory BP \< 135/\<85mmHg, on no treatment. Partial clinical cure is BP \< 135/\<85 mmHg on the same or fewer drugs, not including a K+-sparing diuretic.
Time frame: 12 months
Complete biochemical cure of PA in this cohort of patients that qualify for adrenalectomy.
This is defined as (whilst off medications that might alter serum potassium or the RAS) by both: 1. normalization of serum potassium and normalization of ARR or 2. elevated ARR and either baseline PAC \<190pmol/L, or normal confirmatory test (saline infusion test or captopril challenge test).
Time frame: 12 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Mary University of London